Nolvadex-D (Tamoxifen Citrate)

Tamoxifen Citrate acts on estrogen‑driven breast cancer pathways and is indicated for several clinical scenarios.

• Estrogen‑receptor‑positive early‑stage breast cancer: used as adjuvant therapy to lower recurrence after surgery.
• Metastatic breast cancer: employed to control disease progression in advanced cases.
• High‑risk women: prescribed for risk reduction to prevent development of breast cancer.

• Tamoxifen Citrate binds competitively to estrogen receptors in breast tissue, acting as an antagonist that blocks estrogen‑mediated proliferative signaling. In bone and uterine tissue it exhibits partial agonist activity, preserving bone density while still inhibiting tumor growth driven by estrogen. The drug is metabolized primarily by CYP2D6 to active metabolites that sustain receptor blockade.

Tamoxifen Citrate may cause a range of adverse reactions, most of which are dose‑independent and reversible upon discontinuation.

Common Side Effects

• Hot flashes: sudden feeling of warmth, often with sweating.
• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Fatigue: persistent tiredness not relieved by rest.
• Vaginal discharge or dryness: changes in genital secretions.
• Menstrual irregularities: altered cycle length or flow.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Endometrial cancer: abnormal uterine bleeding or pathology.
• Severe liver dysfunction: jaundice, elevated transaminases.
• Stroke or cerebrovascular accident.
• Anaphylaxis or severe allergic reaction.
• Visual disturbances: retinal changes or cataracts.

When prescribing Tamoxifen Citrate, clinicians should observe several safety measures.

• Monitor liver function: assess hepatic enzymes before initiation and periodically during therapy.
• Assess thromboembolic risk: avoid use in patients with a history of clotting disorders.
• Evaluate uterine health: consider baseline gynecologic assessment for endometrial changes.
• Pregnancy and lactation: contraindicated; ensure effective contraception for women of child‑bearing potential.
• Drug interactions: review concomitant medications that affect CYP2D6 metabolism.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Tamoxifen Citrate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): markedly reduce formation of active metabolites.
• Estrogen‑containing therapies (hormone replacement, oral contraceptives): antagonize therapeutic effect.
• Anticoagulants (warfarin): may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely)

• Moderate CYP2D6 inhibitors (e.g., sertraline, duloxetine): may modestly lower efficacy.
• NSAIDs: additive risk of thromboembolic events.
• Herbal supplements such as St. John’s wort: potential induction of CYP3A4, altering drug levels.